Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05667870
Other study ID # S66590
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 20, 2023
Est. completion date June 2025

Study information

Verified date June 2023
Source KU Leuven
Contact Philip Moons, PhD, RN
Phone 016/373315
Email philip.moons@kuleuven.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Many childhood-onset diseases used to be lethal. Improved life expectancy yield that most patients can survive into adulthood, to date. However, survivors of childhood-onset diseases often develop morbidities that suggest accelerated aging. Indeed, age-related conditions are observed sooner and more frequently in people with childhood-onset diseases. Congenital heart disease (CHD) is a typical example of a childhood-onset disease and is the most common birth defect, comprising a spectrum of mild, moderate and complex heart defects. Recent studies showed that age-related morbidities occur more often and at an earlier age in these patients. The overall goal of this project is to quantify and understand disparities in chronological and biological age over the lifespan in CHD patients.


Description:

Three main research objectives are proposed: Objective 1: The investigators will determine the biological age in patients with CHD across the lifespan, using established and novel biomarkers for aging, and assess the disparity with chronological age. Objective 2: The investigators will identify clinical, behavioral, psychological and social predictors of aging in patients with CHD. Objective 3: The investigators will investigate the difference in biological-chronological age disparity between patients with CHD and healthy counterparts. Three studies will be performed to investigate these objectives: Study 1: Newborns with CHD - The aim is to (i) compare telomere length in newborns with or without CHD; and (ii) to assess pregnancy-related/clinical and mother-related (behavioral, psychological, social) predictors of telomere length in newborns with CHD. Study 2: (Young) adults with CHD - This study aims to (i) compare telomere length in age strata of (young) adults with or without CHD; (ii) to assess clinical, behavioral, psychological, and social predictors of telomere length in patients with CHD; and (iii) to explore the relationship with functional outcomes, such as frailty and cognition. Study 3: Epigenetic clock in adults with CHD - This study focusses on (i) assessing the biological age by measuring DNA methylation in mild, moderate and complex heart defects, and (ii) determining if the disparity between biological and chronological age is a function of anatomical complexity and functional status of the patients and (iii) comparing the epigenetic clock of adults with and without CHD.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility 1. Newborn with CHD and mother Inclusion: - Newborns with CHD who are diagnosed and born in UZ Leuven or UZ Gent - The mother is able to adequate fill out the questionnaires - Informed consent is signed Exclusion: - The mother does not speak Dutch - The heart defect falls within a syndrome condition (e.g., Down syndrome, 22q11 deletion) - Very mild heart defects such as a patent foramen ovale, an open ductus of Botalli (no intervention needed), spontaneous closure of ASD/VSD, an isolated mild peripheral pulmonary stenosis 2. Adults with CHD - study 2 Inclusion: - = 18 years of age at the moment of study inclusion - Diagnosed with CHD - Follow-up at the UZ Leuven or UZ Gent - Signed informed consent - Physical, cognitive, and language abilities to complete self-report questionnaires/ assessment tests Exclusion: - Not speaking Dutch - Very mild heart defects such as a patent foramen ovale, an open ductus of Botalli (no intervention needed), spontaneous closure of ASD/VSD, an isolated mild peripheral pulmonary stenosis - The heart defect falls within a syndrome condition (e.g., Down syndrome, 22q11 deletion) 3. Adults with CHD - study 3 Inclusion: - Included in study 2 - Between 30-50 years of age at the moment of study inclusion - Follow-up at the UZ Leuven or UZ Gent - Signed informed consent - Physical, cognitive, and language abilities to complete self-report questionnaires/ assessment tests - Having one of the following CHD conditions: isolated arterial septal defect, isolated ventricular septal defect, tetralogy of Fallot, coarctation of the aorta, Fontan operation or systemic right ventricle. Exclusion - Not speaking Dutch - The heart defect falls within a syndrome condition (e.g., Downsyndrome, 22q11 deletion) 4. Health volunteers Inclusion: - Male or female healthy volunteers of the Red Cross - Aged 18 - 65 years at the moment of inclusion - The healthy volunteers must match with the patients included in study 2 based on age and sex - Signed informed consent - The requirements of the Red Cross for blood donation are fulfilled Exclusion: - Medical history of cardiac, pulmonal, renal or liver disease, chronic anemia, blood clotting disorder - Not speaking Dutch - Pregnancy - Born with a heart condition

Study Design


Locations

Country Name City State
Belgium Ghent University Hospital Ghent
Belgium University Hospital Leuven Leuven

Sponsors (3)

Lead Sponsor Collaborator
KU Leuven Hasselt University, University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Telomere length Telomere length will be measured on umbilical cord blood from newborns and on peripheral blood from adults with and without CHD. Baseline
Secondary Clinical, behavioral, psychological and social predictors of telomere length This will be studied by using the life history calendar in adults. In newborns, a pregnancy history calendar and correlation with the maternal telomere length will be used. Baseline
Secondary Fall history as a functional outcome of aging in adults with CHD A fall history questionnaire will be used. Baseline
Secondary Frailty as a functional outcome of aging in adults with CHD The Fried method is used for assessment of frailty and consists of five parts: self-report questions about unintentional weight loss, exhaustion and physical activity, an assessment of weakness performed using a handgrip dynamometer, and a walk test. A patient is considered non-frail, pre-frail and frail if, respectively, 0, 1-2 or 3/more components are present. Baseline
Secondary Cognitive impairment as a functional outcome of aging in adults with CHD The Montréal Cognitive Assessment Screener (MoCA) is used for assessment of cognitive function. The maximum score is 30 points, a score of 26 or higher is considered normal. A lower score indicates a worse cognitive function. Baseline
Secondary Epigenetic clock in adults with and without CHD This will be examined based on DNA methylation. Baseline
Secondary hsCRP in adults with CHD Baseline
Secondary Retina scan in adults with CHD This will only be performed on patients included in Leuven Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05330338 - Genetics of Ventriculo-arterial Discordance N/A
Withdrawn NCT03405636 - Xeltis Pulmonary Valved Conduit Safety and Performance Study N/A
Completed NCT02443662 - Colloid Osmotic Pressure in Patients With Fontan Circulation
Terminated NCT02519335 - Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation Phase 1
Completed NCT01835392 - Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery N/A
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Completed NCT03035552 - CTICU Pacifier Activated Music Player and Mother's Voice N/A
Recruiting NCT04581668 - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease N/A
Enrolling by invitation NCT04866537 - Evaluation of the Diagnostic Performance of Specialized Fetal Cardiac Ultrasound in the CPDPN - Arc Alpin Network
Completed NCT03049540 - Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function Phase 3
Completed NCT02377674 - Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection N/A
Completed NCT01679275 - Pre-operative Cerebral Oxygenation in Neonates With Congenital Heart Disease
Terminated NCT00543309 - Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery Phase 2
Completed NCT03957512 - Livet Skal Leves (A Life to Live)
Recruiting NCT06005428 - Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Phase 2
Recruiting NCT02691689 - Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions N/A
Completed NCT02306057 - Fluid Balance in Children Undergoing Fontan Surgery N/A
Recruiting NCT02157597 - NIRS Guidance Trail in Children's Heart Surgery N/A
Completed NCT01570933 - Feasibility Study Over the NAVA Mode in Noninvasive Ventilation After Cardiac Surgery in Infants. Phase 4
Completed NCT00396877 - Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation Phase 3